SYRE vs TRVI Stock Comparison

SYRE currently leads TRVI in this stock comparison, with AIQ scores of 64 vs 63. The clearest difference is momentum, while TRVI has the stronger quality profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 1 points
SYRE
Healthcare
vs
TRVI
Healthcare
SYRE
Spyre Therapeutics, Inc.
Leads
Price
$104
Day move
+1.06%
AIQ Score
64/100
Best edge
Momentum
Sector
Healthcare
TRVI
Trevi Therapeutics, Inc.
Price
$13.65
Day move
+0.22%
AIQ Score
63/100
Best edge
Quality
Sector
Healthcare

What is the main difference between SYRE and TRVI?

SYRE leads the current stock comparison as Spyre Therapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Spyre Therapeutics, Inc. vs Trevi Therapeutics, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 60/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 2/10

SYRE leads

SYRE leads by 1 AIQ points, primarily on Momentum, having only recently taken the lead back from TRVI.

Fragile: 1 of 4 evidence groups support SYRE, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 1 of 4Comparison trend: Reversed
SYRE

Spyre Therapeutics, Inc.

Leads
AIQ Score
64/100
AIQ Edge Score
7/10
TRVI

Trevi Therapeutics, Inc.

AIQ Score
63/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors SYRE over TRVI, 64 versus 63 as of Nov 15, 2026. SYRE's advantage is driven primarily by stronger momentum, while TRVI holds the stronger quality profile. SYRE also shows the stronger technical structure relative to its 50-day moving average. 1 of 4 covered evidence groups favor SYRE today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. SYRE lead: Reversed — TRVI led by 1 AIQ points 30 sessions ago; SYRE now leads by 1.

Compare Spyre Therapeutics, Inc. and Trevi Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

SYRE
+617.2%
TRVI
+1181.7%

Price return comparison

Growth of $10,000, price only

SYRE $71,724 · TRVI $128,169

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare SYRE and TRVI against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

SYRE advantage
0
TRVI advantage
  • Momentum81 vs 52
    SYRE +29
  • Quality61 vs 82
    TRVI +21
  • Risk Resilience53 vs 51
    Even

1 of 4 evidence groups favor SYRE. SYRE’s edge is concentrated in momentum; TRVI keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

SYRE+2 AIQ

Largest factor move: Momentum +2

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.75x)
TRVI+3 AIQ

Largest factor move: Momentum +6

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.68x)
  • TRIX Bullish Signal — bullish, momentum, short horizon

SYRE's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — SYRE and TRVI both carry a full feed there.

The central trade-off

SYRE (Spyre Therapeutics, Inc.): the stronger current systematic profile, led by momentum.

TRVI (Trevi Therapeutics, Inc.): the counter-case, on quality, fundamentals — but at materially higher volatility, 76.9% against 59.5%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

SYRE

SYRE on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

TRVI

TRVI on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

SYRE

SYRE on the Momentum factor, by 29 points.

Lower downside

SYRE

SYRE carries the lower 1-month annualized volatility.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureSYRETRVINote
Implied upside to target+18.1%—Level
Target dispersion+11.4%—Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1811Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

1 of 4 covered evidence groups favor SYRE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreEven64 vs 63
FundamentalsTRVIrevenue growth 0% vs 0%; EPS growth -161.1% vs -18.2%; TTM ROE -9.1% vs -7.1%
ValuationNot coveredNot covered
TechnicalsSYREPrice vs 50-day 13.7% vs -2.7%; vs 200-day 35.7% vs -6%
Risk ResilienceEvenRisk Resilience 53 vs 51
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of SYRE and TRVI and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
  • Only 1 of 4 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SYRE.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

SYRE lead: Reversed — TRVI led by 1 AIQ points 30 sessions ago; SYRE now leads by 1.

May 27SYRE leads above the line · TRVI leads belowNov 13
Today
SYRE +1
64 vs 63
7 sessions ago
Level
62 vs 62
30 sessions ago
TRVI +1
57 vs 58
90 sessions ago
TRVI +10
69 vs 79

The lead changed hands once in this window, most recently on Jun 15 when TRVI moved ahead of SYRE.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

SYREConflicted

4 bullish / 1 bearish / 2 neutral, conflicted

Only SYRE

  • Golden Cross Active — bullish, trend, long horizon (19.32%)
  • Uptrend Structure Active — bullish, trend, long horizon
TRVIConflicted

2 bullish / 4 bearish / 2 neutral, conflicted

Only TRVI

  • Death Cross Active — bearish, trend, long horizon (3.49%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Downtrend Structure Active — bearish, trend, long horizon

Both carry 5 more signals that do not separate them: ADX Trend Weakening, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish, Low Volume Rally Warning, TRIX Bullish Signal.

SYRE leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

SYREConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.06%, AIQ +2 points).

TRVIConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.22%, AIQ +3 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1TRVI closes the Momentum gap — currently 29 points behind, the largest single contributor to SYRE's edge.
  2. 2TRVI's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3SYRE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

TRVI leads on balance
MetricSYRETRVI
Revenue growth (YoY)0%0%
EPS growth (YoY)-161.1%-18.2%
Gross margin50%0%
Operating margin-276.5%0%
Return on equity (TTM)-9.1%-7.1%
Debt to equity00

Performance

SYRE leads 6 of 6 windows
MetricSYRETRVI
1 week (5 sessions)0.1%-4.7%
1 month (20 sessions)30.2%14.9%
3 months (63 sessions)-0.6%-26.1%
6 months (126 sessions)38.8%-3.9%
Year to date217.5%9%
1 year (252 sessions)343.9%15.2%

Technicals

SYRE has the stronger structure
MetricSYRETRVI
RSI (14)59.448.5
ADX (14)17.922.7
Price vs 50-day13.7%-2.7%
Price vs 200-day35.7%-6%
Volatility (1M, annualized)59.5%76.9%

Risk

Split
MetricSYRETRVI
Beta1.691.38
Sharpe ratio2.570.52
Sortino ratio4.620.8
Max drawdown-27.8%-39.1%
Current drawdown-4.6%-30%
Annualized volatility66.7%59.3%
Value at risk (95%)-4.9%-5.4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, SYRE or TRVI?

On the Algovestiq AIQ Score, SYRE is the stronger of the two as of Nov 15, 2026, scoring 64 against TRVI's 63. The edge comes from momentum. TRVI is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is SYRE or TRVI the better buy right now?

SYRE carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 1 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.

Why does the AIQ Score favor SYRE over TRVI?

The composite weights Quality, Value, Momentum and Risk Resilience. SYRE leads Momentum by 29 points; TRVI leads Quality by 21 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, SYRE or TRVI?

Analyst price targets imply +18.1% upside for SYRE and not covered for TRVI. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, SYRE or TRVI?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, SYRE or TRVI?

TRVI on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, SYRE or TRVI?

SYRE on the Momentum factor, by 29 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, SYRE or TRVI?

SYRE is the more resilient of the two, so the other name carries the higher downside risk. SYRE carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is SYRE more profitable than TRVI?

TRVI leads on the comparable margin measures — gross margin 50% vs 0%; operating margin -276.5% vs 0%; ttm roe -9.1% vs -7.1%.

Is SYRE's lead over TRVI getting stronger or weaker?

SYRE lead: Reversed — TRVI led by 1 AIQ points 30 sessions ago; SYRE now leads by 1. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-06-15, when TRVI moved ahead of SYRE.

What would change the SYRE vs TRVI verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: TRVI closes the Momentum gap — currently 29 points behind, the largest single contributor to SYRE's edge; TRVI's Death Cross Active resolves — a bearish trend rule currently active against it; SYRE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about SYRE and TRVI?

SYRE: 4 bullish / 1 bearish / 2 neutral, conflicted. TRVI: 2 bullish / 4 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on SYRE is Golden Cross Active (bullish, long horizon). On TRVI it is Death Cross Active (bearish, long horizon).

Compare SYRE and TRVI with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.